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Abstract
Background It remains unclear to what extent the brain is
affected by Maroteaux-Lamy syndrome (MPS VI), a progres-
sive lysosomal storage disorder. While enzyme replacement
therapy (ERT) elicits positive effects, the drug cannot cross the
blood–brain barrier. We therefore studied cognitive develop-
ment and brain abnormalities in the Dutch MPS VI patient
population treated with ERT.
Methods In a series of 11 children with MPS VI (age 2 to
20 years), we assessed cognitive functioning and brain mag-
netic resonance imaging prospectively at the start of ERT and
at regular times thereafter up to 4.8 years.We also assessed the
children’s clinical characteristics, their siblings’ cognitive de-
velopment, and their parents’ educational levels.
Results The patients’ intelligence scores ranged from normal
to mentally delayed (range test scores 52–131). In 90 %, their
scores remained fairly stable during follow-up, generally lying
in the same range as their siblings’ test scores (median for
patients=104, median for siblings=88) and comparing well
with the parental educational levels. Native-speaking patients
had higher intelligence test scores than non-native-speaking
patients. Two patients, both with high baseline glycosamino-
glycan levels in their urine and severe mutations in the
arylsulfatase B gene, scored clearly lower than expected.
Patients with pY210C performed best. Brain abnormalities
were aspecific, occurring more in patients with severe
symptoms.
Conclusion Our study shows that cognitive development in
MPSVI patients is determined not only by familial and social-
background factors, but, in patients with a severe form of the
disease, also by the disease itself. Therefore in patients with
severe disease presentation cognition should be monitored
carefully.
Introduction
Maroteaux-Lamy syndrome (MPS VI, OMIM #253200) is a
lysosomal storage disease caused by a deficiency of the en-
zyme arylsulfatase B, which leads to storage of dermatan sul-
phate (a glycosaminoglycan, GAG). Its characteristic clinical
features include short stature, bone abnormalities, sensory per-
ception disorders, corneal clouding, carpal tunnel syndrome,
spinal cord compression, and reduced life expectancy
(Azevedo et al. 2004; Giugliani et al. 2007; Neufeld and
Muenzer 2001; Spranger et al. 1970; Stumpf et al. 1973;
Valayannopoulos et al. 2010). The disease spectrum varies
from a rapidly progressive form, to milder variants with later
onset of symptoms. Disease severity is related to urinary GAG
levels (Brands et al. 2013a, b; Giugliani et al. 2007; Swiedler
et al. 2005; Valayannopoulos et al. 2010). In 2007, enzyme
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replacement therapy (ERT) with recombinant human
arylsulfatase B was registered as a treatment for MPS VI.
Although this has positive effects on various tissues (Brands
et al. 2013a, b; Decker et al. 2010; Harmatz et al. 2008;
Harmatz et al. 2010), it is assumed that ERT cannot pass the
blood–brain barrier. While progressive mental retardation is
common in other types of mucopolysaccharidoses (Neufeld
and Muenzer 2001), reports on cognition in MPS VI patients
are inconsistent (Azevedo et al. 2013; Spranger et al. 1970;
Vestermark et al. 1987). Several reports have indicated that
cognition in MPS VI patients is normal. A recent cross-
sectional study among Brazilian patients reported mental re-
tardation in one third of the patients, but also indicated that
severe visual and/or hearing deficits might have influenced the
test results (Azevedo et al. 2013). Many patients had brain
abnormalities.
We prospectively studied the mental development andMRI
findings in the Dutch MPS VI patient population to increase
insight into 1) long-term cognitive outcome, 2) the potential
influence of social and familial background on intelligence, 3)
cognitive outcome relative to the urinary GAG levels and gene
mutations, and 4) the potential relationship between structural
abnormalities of the brain and cognition.
Methods
Patients
All Dutch patients with Maroteaux-Lamy syndrome treated
with ERT participated in this long-term standardized follow-
up study, which was performed at the Center of Lysosomal
and Metabolic Diseases at Erasmus MC University Medical
Center in Rotterdam. MPS VI was diagnosed on the basis of
GAG analysis in the urine followed by enzyme assay on leu-
kocytes and fibroblasts, and then by mutation analyses in the
Arylsulfatase B gene (Brands et al. 2013a, b). Patients were
treated with the registered dose of 1 mg/kg/weekly recombi-
nant human arylsulfatase B (galsulfase, Naglazyme®,
Biomarin Corporation). None had received hematopoietic
stem-cell transplantation.
Study protocols were approved by the Institutional Review
Board. Written informed consent was provided by all patients
and siblings participating in this study, if necessary in con-
junction with their parents.
Intelligence
Each year, patients underwent standardized cognitive assess-
ments, for which we used the following: the Griffith Mental
Development Scales (Griffiths 1984, 1986); the Bayley Scales
of Infant Development (van der Meulen et al. 2002); and the
Wechsler Intelligence Scales (Wechsler Intelligence Scales
Children-third edition; 6–16 years, or Wechsler Adult
Intelligence Scales-third edition; > 16 years) (Kort et al.
2005). For children with impaired hearing, we used the
Snijders-Oomen Nonverbal Intelligence Test-Revised (SON-
R 2½-7) (Tellegen et al. 2008).
To investigate social and familial background, we com-
pared each patient’s intelligence test score with that of their
sibling or siblings. Patients and siblings were tested by three
pediatric neuropsychologists (F.K.A., B.J.E., and R.L.v.d.W.).
We also collected information on the parents’ native language
and highest educational level, and on patients’ and siblings’
school performance.
Brain MRI
Brain magnetic resonance imaging (MRI) was performed reg-
ularly, and the baseline MRI and most recent MRI were used
to determine change over time. The choice of parameters was
based on literature review, being deduced particularly from
four articles on brain abnormalities in patients with MPS VI
(see Supplement) (Azevedo et al. 2013; Gabrielli et al. 2004;
Lee et al. 1993; Seto et al. 2001). Two observers evaluated all
MRIs on T2, FLAIR sequence: a physician assistant trained
for this job (M.B.), and a pediatric neuroradiologist (M.H. L.).
Statistics
Performances in the psychological tests were compared
against the normative data of the Dutch population. The mean
score for each of these tests is 100, with a standard deviation
(SD) of 15 points. A score above 84 reflects normal develop-
ment, a score between 84–70 indicates mild developmental
delay, and a score below 70 severe developmental delay. Per
patient, a difference was defined as a deviation of more than
1.5 standard deviations between total intelligence test scores
(Lezak et al. 2012). The Mann–Whitney U test to determine
differences between groups was used. All analyses were per-
formed with SPSS for Windows (version 20, SPSS Inc.,
Chicago, IL).
Results
Patients characteristics
Eleven children with MPS VI were included in this study;
among them were two sibling couples. Patients were of
Dutch (4), Turkish (4), Moroccan (1), Pakistani (1) and
Guinean (1) ancestry. Seven had consanguineous parents.
Patient characteristics are summarized in Table 1.
The median age at presentation of symptomswas 2.0 years;
at diagnosis it was 5.1 years, and at baseline (start of enzyme
therapy) it was 6.8 years. One patient was assessed at baseline
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only (patient 11). The other patients had at least a
follow-up of two years (three assessments) or longer,
range 0–4.8 years.
Cognitive development at baseline and during follow-up
Forty-two intelligence tests were performed in the 11 patients
(age range 2 to 20 years). Figure 1a shows the patients’ total IQ
(TIQ) scores expressed against duration of enzyme therapy;
Fig. 1b shows the total IQ scores expressed against chronolog-
ical age. Six patients scored above the critical threshold of nor-
mal intelligence (>84) at all time points. At baseline, the test
scores reflected levels of development that ranged from mildly
delayed to above average; the group’s median intelligence test
score was normal (87, range 73–129, n=11). During follow-up,
cognitive development remained stable (one year therapy me-
dian=88, range 59–123, n =10; two years=89, range 52–123,
n=10; three years=94, range 60–131, n=7). Expressed against
chronological age, the scores also remained stable for the var-
ious age categories. However, there was one exception: over a
period of 17 months from baseline, patient 3 (aged 1.9 at base-
line) deteriorated over 30 points (2 standard deviations).
His behavior was diagnosed as Autistic disorder. Until
age 20 months, his skull size increased significantly
(from 0 SD toward +2,5 SD) and he had frontal bossing
and a dolichocephalic skull shape. While MRI showed
prominent ventricles, lumbar puncture did not show
raised intracranial pressure.
Fig. 1 Cognitive development in 11 patients with Maroteaux-Lamy
syndrome. (a) Long-term cognitive development expressed against
duration of ERT, and (b) expressed against chronological age. The first
assessment of patient 5 was based on one subscale score (the performance
scale); due to shyness and withdrawn behavior, the other subscales were
unreliable. (c) Patients’ total intelligence test scores at baseline versus
urinary GAG level at baseline, relative to the siblings’ IQ scores. ■=
scores similar to siblings’, o=scores below siblings’, Δ=no siblings. a=
this child’s sibling had an extraordinarily high test score (IQ=139). b=
this child was patient 3 in Fig. 1a and b. (d) Total intelligence test scores
related to mutation analysis—grouped by identified mutations
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Disharmonic profiles were found in all patients and in 25 of
the 42 tests performed; there was no consistency in dishar-
monic profiles.
Education
Six of the 11 patients were attending or had successfully com-
pleted regular schools, three of whom required extra support
(remedial teaching), due either to dyslexia (n=2) or to mildly
delayed IQ scores. The five other patients attended special
schools for sick children (n=3) or for children with motor
disabilities (n=2).
Social and familial background
Siblings
Seven healthy siblings of seven patients agreed to be tested by
a neuropsychologist as part of this study. The siblings of two
other patients agreed only to inquiry of their school data. The
remaining two patients had no siblings. The intervals between
the patients’ tests and those of their sibling/siblings ranged
between 5 and 9 months.
The siblings’ overall intelligence test scores were largely
similar to the patients’ total test scores (MannWhitneyU Test:
patients median 104 range 68–131; verbal 96 range 74– 25,
performal 104 range 66–128, n=7; siblings median 88 range
77–139; verbal 94 range 75–135, performal 84, range 81–150,
n=7). Five healthy siblings had harmonic profiles. The sixth
sibling had a higher score in the verbal domain than in the
performal domain; in the seventh it was the other way around.
Unfortunately, the siblings of the two patients with the
lowest IQs (patients 3 and 5) were the ones who did not want
to be tested. However, inquiry after their school results
showed that these healthy siblings attended regular schools
without needing special assistance; to date, they had never
failed to be promoted to the next grade. On the basis of these
school results, it was concluded that their intelligence was
likely to be within the normal range (TIQ≥85), unlike that
of their affected siblings, whose scores indicated severe
delays.
Parents
All parents’ highest parental education levels were obtained.
These ranged from finishing primary school to obtaining a
university degree. We found an association between the par-
ents’ educational level and the level of the patients’ and their
siblings’ test scores, most children of parents with a higher
educational level having higher intelligence test scores and
vice versa.
Seven of the 11 children had non-native speaking parents
and were being raised bilingually. On average, patients of
native Dutch-speaking parents had higher test scores (4/4 pa-
tients had normal to above normal intelligence at all times;
range 94–131) than children with non-native-speaking parents
(2/7 patients had normal test scores at all times; range 52–
104).
Age of diagnosis, GAG levels, genetic mutations
The disease was considered to be more severe in four patients
(patients 2–5). They had presented at a young age (range of
age at diagnosis 1.8–3.4 years) and excreted the highest of
GAG levels in their urine at baseline (>300 μg/mg creatinine).
Severe cardiomyopathy was present in three of the four pa-
tients. Figure 1c plots the patients’ GAG levels against their
total IQ. Three of the four patients with high GAG levels
(>300 μg/mg creatinine) had a mild or severe developmental
delay (IQ<85), against two of the seven patients with low
GAG excretion.
Figure 1d categorizes the patients according to their muta-
tions. The first group consisted of patients who were homo-
zygous for the p.R152W mutation (n=3, all of Turkish
Ancestry). The second group had a p.Y210C mutation com-
bined with either p.P313A or p.R327X (n=4, all of Dutch
Ancestry). The third comprised the patients with other muta-
tions. Patients with the p.Y210C mutation had the highest
total intelligence test scores.
Brain abnormalities
During follow-up, all children had at least two brain MRI
scans. Five had their first MRI before the start of ERT.
Median age at the first MRI was 7.4 years (range 1.8–18.0)
and median age at the second was 10.8 years (range 4.1–20.5).
Median time between the twoMRIs was 2.6 years (range 1.2–
5.7). See Table 2 for a detailed description of the results.
Common findings at baseline were enlarged Virchow
Robin spaces (in the basal ganglia and in the white matter);
patchy white matter abnormalities (especially in the occipital
area, but also in the frontal and periventricular area); widened
sinus rectus, a thinner corpus callosum, and mild compression
of the spinal cord.
It is noteworthy that the patchy and diffuse white matter
abnormalities became less intense over time and sometimes
even disappeared (Fig. 2).
Brain abnormalities were found in a higher number of se-
verely affected patients than in patients who were relatively
mildly affected: 4/4 of the severely affected patients had
Virchow Robin spaces in white matter vs. 1/7 of the mildly
affected patients (MRI 2); 4/4 had patchy white-matter signal
changes vs. 1/7 (MRI 1); and 3/4 had thin corpus callosum vs.
2/7 (both MRIs).
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Miscellaneous
All patients visited an ophthalmologist and underwent hearing
tests once and twice a year. Seven out of 11 patients needed
glasses, all for hyperopia (4/4 were severely affected patients
and 3/7 mildly affected patients). Four patients developed
mild to moderate conductive hearing loss, and hearing adds
were fitted and adjusted if necessary (range 7–43 dB right ear;
2–53 dB left ear) (Brands et al. 2013b; three of these patients
were severely affected). At time of IQ testing, hearing and
vision problems were sufficiently compensated (Table 1).
Patients were regularly examined for carpal tunnel syndrome
and five patients underwent carpal tunnel release. At the age
of 5, patient 4 received a ventriculoperitoneal shunt for in-
creased intracranial pressure. All patients required hospital
admissions for medical procedures requiring general anaes-
thesia. The number of interventions ranged from 1 to 11, with
a median of 5. The two most severely affected patients
underwent 11 and 7 procedures.
Discussion
To date, the extent to which MPS VI affects mental outcome
has remained unclear. Our study shows that cognitive devel-
opment in these patients is determined not only by familial
and social-background factors, but, in patients with a severe
form of the disease, also by the disease itself.
Based on the accumulated data of the literature and our
study (Azevedo et al. 2013; Spranger et al. 1970;
Vestermark et al. 1987), we conclude that, just as in other
types of Mucopolysaccharidoses (Neufeld and Muenzer
2001), cognitive development in MPS VI presents as a spec-
trum from normal to delayed. However, the spectrum in MPS
VI seems milder than in other mucopolysaccharidoses that
affect the brain, such as MPS I, II, and III.
Whereas previous studies were cross sectional, our pro-
spective approach found that cognition remained fairly stable
in 90% of our patients during follow-up periods that lasted up
to 4.8 years. Progressive mental retardation was noted in only
one of our 11 patients.
A number of variables influenced cognitive development
in our patients with MPS VI. The most important factors ap-
peared to concern social and family background. These pa-
tients were drawn from various cultural backgrounds and
reflected a wide variation in parents’ educational level.
Table 2 Results of baseline MRI
and most recent MRI Rapid progressive Slow progressive
Domain MRI 1 MRI 2 MRI 1 MRI 2
Enlarged Virchow Robin Basal nuclei 2/4 2/4 3/7 4/7
White matter 3/4 4/4 0/7 1/7
Corpus Callosum 1/4 2/4 0/7 0/7
Large lesions 1/4 1/4 0/7 0/7
White matter Patchy lesion 4/4 2/4 1 1/7 1/7
Diffuse lesion 0/4 0/4 1/7 1/7
Ventricular enlargement FOHWR 0/3 1/4 1/7 1/7
Intracranial pressure Widened sinus rectus 3/4 3/4 2/7 3/7 2
Atrophy All fissures and sulci involved 0/4 0/3 0/7 0/7
Thinner corpus callosum 3/4 3/4 2/7 2/7
Mild compression of the spinal cord 3/4 3/4 2/7 3/7
Total abnormalities 20/43 21/43 12/77 16/77
1 White-matter abnormalities disappeared in two patients. In the remaining two patients, white-matter abnormal-
ities decreased, but were still visible
2 1/7 showed a slight increase, possibly due to differences in technique
Fig. 2 Longitudinal brain magnetic resonance imaging (MRI). (a) The
patient was 2 years of age at firstMRI. (b) The patient was 4.5 years old at
the second MRI. The arrows indicate a delay in myelination in the
occipital region (slices are at slightly different levels, due to the quality
of MRI). Please note the presence of enlarged Virchow Robin spaces in
the white matter in the second MRI (not present in the first MRI)
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Patients with non-native speaking parents generally had lower
intelligence test scores when compared to those with native
speaking parents. Also, as five of the 11 patients scored below
average, three of whom had siblings with similar test scores
and parents with relatively low educational levels, we con-
clude that social and familial background factors largely con-
tributed to their relatively low cognitive level. In healthy chil-
dren, cognition is known to be associated with parental edu-
cational level (Bradley and Corwyn 2002), inheritance
(Bouchard and McGue 1981), and native and or non-native-
speaking environments (Kort et al. 2005). Our study shows
that any interpretation of cognitive test results should take into
account social and familial background factors, especially
when the patient population is small and diverse as in ultra-
rare diseases such as MPS VI.
With regard to these social and familial background factors,
we found that two patients clearly had lower test scores than
expected. Both presented before the age of 5 years with severe
symptoms and high GAG excretion in the urine (>300 μg/mg
creatinine). While we concluded that MPS VI-related factors
probably played a role in determining these children’s cogni-
tive level, the picture was not clear-cut: at least one child with
high GAG levels and early disease onset performed reason-
ably well and continued to do so during follow-up. We con-
clude that it is only in children with severe disease presenta-
tion, characterized by high urinary GAG excretion, that there
seems to be a risk of low cognitive levels.
With regard to the effect of the genotype on cognition, we
note that the group of patients with the p.Y210C mutation per-
formed best (Karageorgos et al. 2007). These patients had parents
who were all native-speakers of the national language, and who
all had a high educational level. Similarly, they had siblings
whose intellectual performance was in the highest range.
Earlier, it was reported by Swiedler et al. (2005) that the
p.Y210C mutation was associated with low GAG excretion
and better growth. In three of the four children, p.Y210C was
combined with p.R327X, a nonsense mutation leading to no
production of the arylsulfatase B protein. This indicates that the
secondmutation did not influence the milder phenotype. Patients
3 and 5, who had the lowest intelligence test scores, both had
severe mutations. One of these patients was homozygous for
1142+2 T>C, a mutation affecting the invariant splice donor
sequence that is therefore expected to completely disrupt splic-
ing; the other was homozygous for p.G324V, which leads to
reduced synthesis of arylsulfatase B protein (Brands et al.
2013a).
Despite the seemingly limited influence of MPS VI on cog-
nition at group level, there was a considerable need for special
education services (73 % versus 5 % in the normal population).
In part, this was no doubt explained by physical limitations such
as limited joint mobility, bone deformities, pain, cardiac prob-
lems, and fatigue—medical problems that also substantially in-
creased school absence. Also, the frequent hospitalizations and
surgical procedures may have influenced cognitive ability. It is
unsure whether educational potential was influenced by subtle
neuropsychological deficits that had not been detected by stan-
dard intelligence tests. Although hearing problems and poor eye
sight more often occur in severely affected patients, vision or
hearing deficits were not a main contributor. At the time of test-
ing, they appeared to have been sufficiently compensated by
glasses and hearing aids.
The structural abnormalities detected on our patients’ brain
MRIs were generally mild, fairly aspecific, and similar to
those previously reported (Azevedo et al. 2013; Borlot et al.
2014; Palmucci et al. 2013; Rasalkar et al. 2011; Thorne et al.
2001; Vedolin et al. 2007; Zafeiriou and Batzios 2013).
Patients with rapidly progressive and attenuated disease pre-
sentations had similar types of abnormality. Those with severe
disease had slightly more abnormalities, particularly with re-
gard to the frequency of white matter lesions (patchy lesions,
thinner corpus callosum, and Virchow Robin spaces in the
white matter). The white matter abnormalities found in our
patient group were different from those in other lysosomal
storage diseases such as Metachromatic Leukodystrophy
(Gieselmann and Krageloh-Mann 2010) and Hunter Disease
(Manara et al. 2011), in which such abnormalities are clearly
progressive.
Conclusion
Cognitive development in MPS VI presents in a spectrum that
ranges from normal to delayed. Our study shows that cogni-
tive development in MPS VI patients is determined not only
by familial and social-background factors, but, in patients with
a severe form of the disease, also by the disease itself.
Cognition of patients with these hallmarks should be moni-
tored closely. Furthermore, cognition testing in rare diseases
such as MPS VI should include examination of social and
familial background factors such as parental educational level,
and testing of siblings’ cognitive levels. Such an approach is
especially necessary in small patient populations from varied
cultural backgrounds.
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